[Intermittent androgen deprivation in advanced prostate cancer: a review]. / Die intermittierende Androgenblockade beim fortgeschrittenen Prostatakarzinom - eine Übersicht.
Aktuelle Urol
; 43(2): 115-20, 2012 Mar.
Article
em De
| MEDLINE
| ID: mdl-22222751
ABSTRACT
At present androgen ablation therapy is the therapy of choice for the treatment of metastatic prostate cancer. However, in more than 50 % of the patients the disease will ultimately progress within 2âyears.On the basis of the postulation from Bruchovsky et al. that intermittent androgen deprivation maintains the apoptotic potential, this may lead to a delay in tumour progression. By periodically changing phases from on to off the treatment quality of life for the patient may be improved. Most recent clinical data of phaseâII and III studies imply that IAB is equal effective as CAB. Although data about quality of life and overall survival are still limited, results seem to be comparable. In order to decide which patient groups are most likely to benefit from IAB, final phaseâIII results need to be available.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
/
Antagonistas de Androgênios
Aspecto:
Patient_preference
Limite:
Animals
/
Humans
/
Male
Idioma:
De
Revista:
Aktuelle Urol
Ano de publicação:
2012
Tipo de documento:
Article